Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
Open Access
Abstract
Immunotherapy approaches have advanced rapidly in recent years. While the greatest therapeutic advances so far have been achieved with T cell therapies such as immune checkpoint blockade and CAR-T, recent advances in NK cell therapy have highlighted the therapeutic potential of these cells. Chronic lymphocytic leukemia (CLL), the most prevalent form of leukemia in Western countries, is a very immunosuppressive disease but still shows significant potential as a target of immunotherapy, including NK-based therapies. In addition to their antileukemia potential, NK cells are important immune effectors in the response to infections, which represent a major clinical concern for CLL patients. Here, we review the interactions between NK cells and CLL, describing functional changes and mechanisms of CLL-induced NK suppression, interactions with current therapeutic options, and the potential for therapeutic benefit using NK cell therapies.Keywords
Funding Information
- NCI (R35 CA197734)
- Pelotonia Graduate Student Fellowship
This publication has 274 references indexed in Scilit:
- Association of an increased frequency of CD14+HLA‐DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)British Journal of Haematology, 2011
- Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemiaImmunology, 2011
- Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based studyBritish Journal of Cancer, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cellsLeukemia Research, 2009
- Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte LeukemiasCancer Research, 2009
- Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cellsCancer Immunology, Immunotherapy, 2008
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJournal of Clinical Investigation, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Interleukin 15–mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1Nature Immunology, 2007